GDMT for HFmrEF
I cannot provide guideline-directed medical therapy (GDMT) for heart failure with mildly reduced ejection fraction (HFmrEF) based on the evidence provided, as all the evidence relates to viral hemorrhagic fevers (VHF), not heart failure management.
Critical Clarification Needed
The evidence base consists entirely of guidelines and research about:
- Viral hemorrhagic fevers (yellow fever, Lassa fever, dengue, Crimean-Congo hemorrhagic fever, etc.) 1, 2, 3, 4
- Intracerebral hemorrhage (ICH) management 1
- General bleeding management 5, 6, 7
- Transfusion guidelines 1
None of this evidence addresses heart failure pharmacotherapy, which would include:
- Beta-blockers (carvedilol, metoprolol succinate, bisoprolol)
- ACE inhibitors or ARBs or ARNI (sacubitril/valsartan)
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone)
- SGLT2 inhibitors (dapagliflozin, empagliflozin)
- Diuretics for volume management
What You Need
To answer your question about GDMT for HFmrEF, I would require:
- ACC/AHA Heart Failure Guidelines [@missing@]
- ESC Heart Failure Guidelines [@missing@]
- HFSA Guidelines [@missing@]
- Relevant clinical trials (EMPEROR-Preserved, DELIVER, etc.) [@missing@]
Please clarify if you intended to ask about hemorrhagic fever management, or resubmit with appropriate heart failure evidence if GDMT for HFmrEF is truly your question.